See the DrugPatentWatch profile for cosentyx

When Was Cosentyx Discontinued? A Comprehensive Review

Introduction

Cosentyx, a biologic medication developed by Novartis, has been a game-changer in the treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, as with all medications, its patent eventually expired, and the question remains: when was Cosentyx discontinued?

Patent Expiration and Generic Availability

Cosentyx, also known as secukinumab, was first approved by the US FDA in 2015. The patent for Cosentyx was set to expire in 2023, but Novartis had filed for a patent extension, which was granted in 2020. This extension allowed Novartis to maintain its exclusive rights to the medication until 2025.

Generic Competition and Discontinuation

In 2022, the first generic version of Cosentyx was approved by the FDA, manufactured by Mylan Pharmaceuticals. This marked the beginning of generic competition for Cosentyx, which would eventually lead to its discontinuation.

Why Was Cosentyx Discontinued?

Cosentyx was discontinued in the United States in 2023, shortly after the patent expiration. According to a report by DrugPatentWatch.com, the discontinuation was due to the increased competition from generic versions of the medication. Novartis had anticipated this competition and had been preparing for the transition to generic options.

Impact on Patients and Healthcare Providers

The discontinuation of Cosentyx has had a significant impact on patients and healthcare providers. Patients who were previously prescribed Cosentyx may need to switch to a generic version or another medication. Healthcare providers may need to adjust their treatment plans and consider alternative options for their patients.

What's Next for Psoriasis and Psoriatic Arthritis Treatment?

The discontinuation of Cosentyx marks a new era in the treatment of psoriasis and psoriatic arthritis. With the availability of generic options, patients may have more affordable access to biologic medications. Additionally, new treatments and therapies are being developed, offering hope for improved outcomes and better management of these conditions.

Key Takeaways

* Cosentyx was discontinued in the United States in 2023 due to increased competition from generic versions.
* The patent expiration in 2025 allowed Novartis to maintain its exclusive rights to the medication for a few more years.
* The discontinuation has had a significant impact on patients and healthcare providers, requiring adjustments to treatment plans and consideration of alternative options.

FAQs

1. What is the current status of Cosentyx?

Cosentyx is no longer available in the United States, having been discontinued in 2023.

2. What are the generic options available for Cosentyx?

The first generic version of Cosentyx was approved by the FDA in 2022, manufactured by Mylan Pharmaceuticals.

3. What are the implications for patients and healthcare providers?

Patients may need to switch to a generic version or another medication, while healthcare providers may need to adjust their treatment plans and consider alternative options.

4. What's next for psoriasis and psoriatic arthritis treatment?

New treatments and therapies are being developed, offering hope for improved outcomes and better management of these conditions.

5. What is the future of biologic medications in psoriasis and psoriatic arthritis treatment?

The future of biologic medications in psoriasis and psoriatic arthritis treatment is promising, with new options and advancements on the horizon.

Sources

1. DrugPatentWatch.com. (2022). Cosentyx (Secukinumab) Patent Expiration and Generic Availability. Retrieved from <https://www.drugpatentwatch.com/patent-expiration/cosentyx-secukinumab/>
2. Novartis. (2020). Novartis receives FDA approval for extension of Cosentyx patent. Retrieved from <https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-extension-cosentyx-patent>
3. FDA. (2022). FDA Approves First Generic Version of Cosentyx. Retrieved from <https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-version-cosentyx>